Ex-Retrophin BD chief flips his rare dis­ease start­up on­to Nas­daq via re­verse merg­er with Pro­teon

Pro­teon Ther­a­peu­tics’ lead and on­ly drug for kid­ney and vas­cu­lar dis­eases may not be worth much in in­vestors’ eyes, but its Nas­daq list­ing is prov­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.